Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Influence of educational level on test and treatment for incident hypothyroidism

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Maternal thyroid disease and adiposity in mother and child

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Commentary on Winzeler et al 'Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemia'

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Brain tumours in children and adolescents may affect the circadian rhythm and quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Brain tumours result in sleep disorders in children and adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
OBJECTIVE: To investigate whether pegvisomant treatment in acromegaly induces gradual elevations in endogenous serum growth hormone (GH) levels and whether serum pegvisomant levels predict the therapeutic outcome. PATIENTS AND METHODS: Seventeen patients (6 women), mean age 46·3 years (range: 23·2-76·2), were studied. For each patient, four hospital visits were identified including 'active disease' (no treatment) and last follow-up. At each visit, 12 blood samples were drawn during 3 h including an oral glucose tolerance test (OGTT). Eight patients received a somatostatin analogue in addition to pegvisomant on the last visit. RESULTS: Median (range) pegvisomant doses (mg/day) were 10 (10-10), 15 (10-15) and 15 (10-15) at visits 2, 3 and 4, respectively, and the mean duration of pegvisomant treatment was 17·5 ± 3·2 (SEM) months. Serum IGF-I changed significantly during the treatment period with the highest level at baseline and lowest levels at visits 3 and 4. GH levels increased in a dose-dependent manner during pegvisomant treatment and decreased at visit 4. Changes in IGF-I levels correlated negatively with changes in serum pegvisomant levels between visits. Serum pegvisomant at each visit correlated with baseline growth hormone levels, whereas no associations between serum pegvisomant and either dose, gender, age or body weight were found. CONCLUSIONS: (1) Serum GH levels increased initially, but remained stable during prolonged pegvisomant treatment in patients with acromegaly, (2) serum pegvisomant levels predicted the reduction in serum IGF-I during treatment and (3) the interindividual variation in serum pegvisomant levels seems not predicted by either age, gender or body composition.
Original languageEnglish
JournalClinical Endocrinology
Volume80
Issue number1
Pages (from-to)92-100
ISSN0300-0664
DOIs
Publication statusPublished - 2014

ID: 39031410